News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lixte Biotechnology Announces New Appointment to Board of Directors, Robert B. Royds, M.B.



5/25/2011 10:26:36 AM

Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

PR Newswire

EAST SETAUKET, N.Y., May 25, 2011 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Robert B. Royds, M.B., B.S., M.R.C.P. to the company's Board of Directors.

Dr. Royds is Chair of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, which he founded in 1982. Theradex®, based in Princeton, NJ, with research bases in Europe, Australia, and Japan, provides a full complement of services critical to drug development including regulatory strategy, consulting, pre-clinical toxicology and pharmacology review, preparation of regulatory filings, and clinical trials design. Dr. Royds is responsible for the scientific affairs of the company.

Trained in internal medicine and pharmacology, Dr. Royds has extensive experience in all stages of clinical drug development process. Before founding Theradex®, he was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. He has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. He has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.

"We are extremely pleased that Dr. Royds has joined our Board of Directors. He has had an exceptional experience in all aspects of cancer drug development, especially in the increasingly complex area of efficient clinical evaluation of new anti-cancer drugs with diverse clinical applications," said Dr. Kovach. "Dr. Royds' expertise is particularly valuable to Lixte at this juncture in the clinical development of our lead compounds, especially, LB-100, a novel signal transduction modifier, which has activity against different types of human cancer, alone but especially, in combination with standard anti-cancer drugs.

About Lixte Biotechnology Holdings, Inc.

Lixte is a biotechnology company engaged in development of improved treatments for cancer and methods for detecting cancer. Lixte was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past four years, however, the Company has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to develop new potentially more effective anti-cancer drugs.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The primary focus is on the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme ("GBM"). The research on brain tumors is being conducted with the National Institute of Neurological Disorders and Stroke ("NINDS") of the National Institutes of Health ("NIH") under a Cooperative Research and Development Agreement ("CRADA").

The Company has expanded the scope of its program to other cancers of neural tissue (nerve and brain), including medulloblastoma, the most common brain tumor of children, and neuroblastoma, the most common cancer of children, and to other common cancers of adults including sarcomas, melanomas, and breast cancer

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10-QSB for the quarter ending March 31, 2011.

For additional information, please see:
www.Lixte.com

Investor Relations
Jeff Ramson
212-297-6103
jramson@proactivecrg.com
Pro-Active Capital Resources Group

SOURCE Lixte Biotechnology Holdings, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES